BGB 3111

Drug Profile

BGB 3111

Alternative Names: BGB-3111

Latest Information Update: 17 Mar 2017

Price : $50

At a glance

  • Originator BeiGene
  • Developer BeiGene; Peter MacCallum Cancer Centre
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Waldenstrom's macroglobulinaemia; Mantle-cell lymphoma; Chronic lymphocytic leukaemia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Waldenstrom's macroglobulinaemia
  • Phase II Chronic lymphocytic leukaemia; Mantle-cell lymphoma
  • Phase I B cell lymphoma

Most Recent Events

  • 10 Mar 2017 Phase-II clinical trials in Chronic lymphocytic leukaemia (Second-line therapy or greater) in China (PO)
  • 02 Mar 2017 Phase-II clinical trials in Mantle cell lymphoma (Second-line therapy or greater) in China (unspecified route)
  • 10 Feb 2017 Phase-III clinical trials in Waldenstrom's macroglobulinaemia (Monotherapy, Second-line therapy or greater) in Greece, Spain (PO) (EudraCT2016-002980-33)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top